Concord Biotech Limited has informed the Exchange about Investor Presentation

Concord Biotech reported FY26 revenue of Rs. 1,054.9 Crores, down 12% YoY from Rs. 1,200.1 Crores in FY25. Q4FY26 revenue declined 24% to Rs. 326.1 Crores. EBITDA for FY26 fell 27% to Rs. 367.4 Crores with margins contracting to 34.8% from 42.2% previously. PAT declined 30% to Rs. 259.2 Crores. Management attributed the weakness to delayed EU supplies due to CDSCO Written Confirmation delays, US customer shift to staggered procurement, global tariff uncertainty, Middle East geopolitical headwinds, and a delayed US Veterans Affairs tender. However, gross margins improved 217 bps to 76.7%. The company completed multiple regulatory inspections (USFDA, EU GMP, WHO-GMP), commercialized its new injectable facility, launched Fusidic Acid, commenced supplies to two innovator companies, and established US commercial presence through Stellon Biotech. Management guided optimism for FY27 based on strong order pipeline and customer acquisition momentum.